Drug intelligence / Profile preview

CT002

Development stage: Unknown
Lead developer: Cessatech
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Intranasal

Overview

CT002 is an intranasal formulation of dexmedetomidine being developed by Cessatech for procedural sedation in children, specifically for MRI scans. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that provides sedation and anxiolysis by activating centrally located receptors in the locus coeruleus, inducing a state that mimics natural sleep without significant respiratory depression. This needle-free, non-invasive delivery method is designed for children aged 0-17 years as an alternative to intravenous administration, aiming to improve clinical practice for pediatric patients requiring sedation for diagnostic procedures.

Other names: dexmedetomidine nasal spray

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on CT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT002.

Explore the full profile